
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care has demonstrated strong revenue growth potential, with projected revenues increasing from $1.109 million in 2026 to $1.111 million, and further to $1.229 million in 2027. The company anticipates re-establishing positive new patient start growth in the US at approximately 4% year-over-year, fueled by conversion from multiple daily injections and enhanced access through pharmacy channels. Additionally, Tandem's recent revenue performance exceeded expectations by about $14 million, primarily due to a strong presence in the US market and increased pricing power from pharmacy channel penetration.
Bears say
Tandem Diabetes Care has faced significant operating losses since its inception and fails to guarantee sustained profitability, which raises concerns about its financial stability. The company anticipates flat to slightly declining new patient starts in the U.S. for 2025, with estimated pump shipments reflecting a 4% year-over-year decrease, indicating potential challenges in market demand. Additionally, risks such as competitive pressures, contract negotiations in the pharmacy channel, and inadequate growth from new product launches like the Mobi pump could negatively impact Tandem's future revenue and profitability prospects.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares